Hidradenitis clinical trials
The registry lists 34 studies for Hidradenitis across more than 10 countries. 9 are recruiting or about to start. 5 of them are mainly about Hidradenitis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09. Counting its narrower condition Hidradenitis Suppurativa too: 291 studies, 88 open.
Get an email when these change. Save the Hidradenitis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
MoonLake Immunotherapeutics AG (5) · Incyte Corporation (5) · Sanofi (3) · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (2) · Novartis Pharmaceuticals (2) · Wayne State University (2) · University of North Carolina, Chapel Hill (2) · George Washington University (1)
What is being tested here
Drugs under test in Hidradenitis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Povorcitinib | 2 | 4 | 5 |
| Sonelokimab | 1 | 4 | 5 |
| Duvakitug | 1 | 0 | 1 |
| Remibrutinib | 0 | 2 | 2 |
| Anifrolumab | 0 | 0 | 1 |
| Zunsemetinib | 0 | 0 | 1 |
| Hydroxychloroquine | 0 | 0 | 1 |
| Triamcinolone Acetonide | 0 | 0 | 1 |
| Triamcinolone | 0 | 0 | 1 |
| Amlitelimab | 0 | 0 | 1 |
Drug classes tested here Tyrosine kinase inhibitors (TKIs) 2 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 5, phase 3 first
- Dec 2026A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa · Phase 3 · Incyte Corporation
- May 2027A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) · Phase 3 · Novartis Pharmaceuticals
- Jun 2027A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 3 · Novartis Pharmaceuticals
- Feb 2027A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa · Almirall, S.A.
- Oct 2027A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial) · Spyre Therapeutics, Inc.
Who these studies take
Of the 8 Hidradenitis studies recruiting now, 4 (50%) set no upper age limit and 4 (50%) stop at 75 or younger. 2 (25%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (13%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (13%) | 1 (13%) |
| 18 | 7 (88%) | 7 (88%) |
| 30 | 7 (88%) | 7 (88%) |
| 40 | 7 (88%) | 7 (88%) |
| 50 | 7 (88%) | 7 (88%) |
| 65 | 7 (88%) | 7 (88%) |
| 75 | 5 (63%) | 5 (63%) |
| 85 | 4 (50%) | 4 (50%) |
Across all 34 studies, recruiting or not: 26% stop at 75 or younger and 15% at 65; 24% take children; 3% are for women only and 0% for men only; 9% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 12, 2026.
Started recruiting2
Results posted1
Studies
Recruiting first, then most recently updated. Showing 34 of 34. search them.
- A Study to Investigate Efficacy and Safety of Duvakitug in Adult Participants With Moderate to Severe Hidradenitis SuppurativaRecruitingNCT07812116Phase 22 countries
- Rollover Study for Participants Previously Enrolled in Clinical Trials of PovorcitinibRecruitingNCT06855498Phase 320 countries
- SAR447971 First-in-human StudyRecruitingNCT07629336Phase 11 country
- A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)RecruitingNCT07766005Phase 22 countries
- Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis SuppurativaRecruitingNCT07213973Phase 22 countries
- A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis SuppurativaRecruitingNCT07547813Phase 21 country
- A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis SuppurativaEnrolling by invitationNCT07007637Phase 316 countries
- Constitution of a Prospective Cohort of Patients With Acute Suppurative Hidrosadenitis Followed in the Great West: the COVER Cohort (Verneuil Cohort)RecruitingNCT043520361 country
- Battlefield Acupuncture for Pain in Hidradenitis SuppurativaRecruitingNCT04218422Not applicable1 country
- An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)CompletedNCT06768671Phase 31 country
- A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)CompletedNCT05620836Phase 311 countries
- Tibulizumab Skin Healing and Inflammation Evaluation for Lasting DefenseActive, not recruitingNCT06993610Phase 26 countries
- A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)Active, not recruitingNCT06799000Phase 320 countries
- A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis SuppurativaActive, not recruitingNCT06840392Phase 319 countries
- Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis SuppurativaCompletedNCT05322473Phase 27 countries
- A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis SuppurativaActive, not recruitingNCT06212999Phase 317 countries
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis SuppurativaCompletedNCT06411899Phase 310 countries
- Anifrolumab for Hidradenitis SuppurativaCompletedNCT06374212Phase 21 country
- Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis SuppurativaCompletedNCT06411379Phase 312 countries
- A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis SuppurativaCompletedNCT05620823Phase 312 countries
- Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis SuppurativaTerminatedNCT06118099Phase 211 countries
- Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis SuppurativaTerminatedNCT06555328Phase 26 countries
- ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)CompletedNCT05216224Phase 21 country
- HIDRAdenitis Suppurativa and HEART DiseaseActive, not recruitingNCT059899451 country
- HidraWear Study for Hidradenitis Suppurativa WoundsCompletedNCT04449354Not applicable1 country
- Treatment of Hidradenitis Suppurativa With Eth 755nm Alexandrite LaserCompletedNCT03054155Not applicable1 country
- Wound Etiology and Healing StudyCompletedNCT013520781 country
- Low Dose Radiotherapy for Advanced Hidradenitis SuppurativaTerminatedNCT03040804Not applicable1 country
- Hydroxychloroquine for the Treatment of Hidradenitis SuppurativaCompletedNCT03275870Phase 1/21 country
- 15% TOPICAL RESORCINOL FOR HURLEY I-II HIDRADENITIS SUPPURATIVA.Status unknownNCT040992121 country
- A Randomized Controlled Trial Evaluating the Efficacy of Intralesional Triamcinolone in Hidradenitis Suppurativa.CompletedNCT02781818Not applicable1 country
- Patients With Hidradenitis vs Patients With Psoriasis: Psychological ImpactStatus unknownNCT02999698
- Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin DiseasesStatus unknownNCT019522751 country
- Group Psychotherapy for Patients With Hidradenitis Suppurativa: Effects in Quality of LifeStatus unknownNCT02904408Not applicable1 country